NKTX News and Press, Nkarta Inc. From 05/23/24

2024-05-23 11:48:35 ET Summary Nkarta, Inc. has raised $240.1 million through a stock offering, strengthening its cash position and extending its cash runway to 2027. The company's stock has been trending down, but there are signs of recovery, with a 6.4% increase in share price. ...

2024-05-09 17:25:25 ET More on Nkarta Nkarta: Down 50% Since March With A Clinical Catalyst Ahead Nkarta: NK Cell Therapy Advancement On Two Fronts Nkarta's Strategic Advances In Cell Therapy For Autoimmune Disorders Nkarta announces pricing of stock offering...

Dosing of first patient with NKX019 for lupus nephritis using disease-tailored lymphodepletion expected in first half of 2024 Cash balance of $450.0 million on March 31, 2024, including cash, cash equivalents and investments Strong balance sheet, bolstered by recent $240.1 milli...

2024-05-07 06:30:00 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Three equities stand out among the plethora of alternatives as possible Wall Street game-changers. Each represents a distinct industry: energy, cannabis and biotechnology. The first company...

2024-04-27 15:39:17 ET More on Amgen, Cullinan Oncology, etc. Amgen: I Prefer To Chase Value And Dividends Amgen: The Giant With An Impressive Pipeline Move Over Eli Lilly: Amgen Could Be The Next Obesity Wonder Stock Cullinan Therapeutics expands into autoim...

2024-04-27 10:27:00 ET Summary NKTX is now down over 50% from its March 2024 highs. The company's pipeline includes NKX019, a CAR-NK cell therapy with potential in cancer and autoimmune disease. NKTX has already produced some data with NKX019 in oncology with more data coming ...

2024-04-06 21:30:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-03-25 16:03:27 ET Summary Release of results from the phase 1 study, using NKX019 for the treatment of patients with relapsed/refractory NHL, expected mid-2024; this is using a compressed dosing schedule. The global non-Hodgkin's Lymphoma market is expected to reach $20 billi...

2024-03-25 10:00:59 ET More on Health Care Select Sector SPDR XLV: Low-Cost Exposure To A Defensive Sector, While Achieving Strong Performance Healthcare In 2024: Navigating The Biopharma Bull Run Johnson & Johnson, Boston Scientific least shorted stocks in S&...

2024-03-25 07:27:03 ET DENVER, Colo., Mar 25, 2024 ( 247marketnews.com )- Nkarta, Inc. (NASDAQ: NKTX ) stated, this morning, that it priced an underwritten offering of 21,010,000 shares of its common stock at a price of $10.00 per share and pre-funded warrants to purchase 3,000,031 ...